עברית

Health Systems Can Monitor Distant Pregnant Patients With Clinician-Reviewed Home Ultrasound

For health system and maternal care leaders: which monitoring tools serve patients in maternity care deserts, and where home ultrasound fits.

TL;DR

  • A maternity care desert is a county with no obstetric clinicians or birthing facilities, and 34.6 percent of U.S. counties meet that definition.
  • ACOG’s April 2025 consensus supports tailored visit schedules, telemedicine, and home monitoring, which gives health systems a clinical basis for remote prenatal programs.
  • A health system can build hybrid prenatal care by combining telehealth visits, home blood pressure monitoring, fetal heart tracing, and clinician-reviewed home ultrasound, because each serves a complementary purpose.
  • Home ultrasound enables at-home ultrasound imaging, including fetal heart rate assessment, with remote review by healthcare professionals, and it complements in-person diagnostic ultrasound without replacing it.
  • Pulsenmore ES is a physician-prescribed home prenatal ultrasound system with FDA De Novo marketing authorization that health systems can add to a remote monitoring program.

For patients living far from a clinic, hybrid prenatal care can bring essential elements of care closer to home. By combining telehealth consultations with connected monitoring technologies, including clinician-reviewed home ultrasound, healthcare providers can maintain clinical engagement between in-person visits. Each technology serves a complementary purpose, from maternal blood pressure monitoring to fetal heart rate assessment and ultrasound imaging. In-person visits remain essential for comprehensive diagnostic evaluations and care requiring direct clinical assessment.

Why distance defines access in maternity care deserts

March of Dimes’ 2026 report found that 34.6 percent of U.S. counties are maternity care deserts, home to 2.4 million women of reproductive age and 149,000 births a year. Women in these counties travel about three times farther on average to reach labor and delivery services than women in counties with full access.

The same report identified at least 96 labor and delivery unit closures across 35 states from January 2024 to May 2026. In nearly 60 percent of the affected counties, the closed unit was the only local birthing facility, and recent closures added an average of 25 minutes of travel. As access to maternity services becomes increasingly limited, hybrid prenatal care offers a way to bridge the growing distance between patients and providers. By combining in-person visits with telehealth and clinician-reviewed home monitoring, healthcare systems can extend access to prenatal care while reducing the need for unnecessary travel.

What ACOG guidance allows

ACOG’s Clinical Consensus No. 8, published in April 2025, supports tailoring prenatal care to the patient. Michigan Medicine’s summary of the guidance describes fewer, more widely spaced visits for uncomplicated pregnancies, supplemented by telemedicine and home monitoring devices. The systematic reviews behind it found no differences in maternal and neonatal outcomes among average-risk patients on targeted schedules or telemedicine compared with traditional schedules, and found high-quality evidence for home blood pressure monitoring. Some higher-risk patients still need more frequent visits and monitoring.

What each monitoring option covers

No single tool covers every need. The table matches each monitoring need to its tool and shows where home ultrasound applies.

Monitoring needTypical toolWhat it coversRole of Pulsenmore ES
Mother’s blood pressure between visitsHome blood pressure cuff with remote reviewMaternal hypertension, supported by high-quality evidenceRuns alongside
Baby’s heart rate patternFetal heart monitor with remote reviewHeart rate tracingComplementary
Fetal heart rateHome ultrasound reviewed by a clinicianFetal heart rate assessment from home-acquired ultrasound imagesCore function
Anatomy, growth, diagnostic findingsIn-person ultrasoundFull diagnostic assessmentNot replaced, stays in the pathway
Specialist inputTelehealth visit with a maternal-fetal medicine teamConsultation and care planningClinician-guided mode lets the clinician direct a scan during the visit

Sheba Medical Center’s hospital-at-home program for high-risk pregnancy shows several of these tools in one model. It combines daily remote visits, glucose monitoring, fetal heart tracing from INVU by Nuvo, and fetal ultrasound from Pulsenmore, and it had 93 patients by February 2025.

How Pulsenmore ES works for patients far from a clinic

Pulsenmore ES has three parts: a handheld transducer that docks to the patient’s smartphone, an app that guides the scan, and a clinician dashboard for review. In app-guided mode, the patient scans independently and submits the scan for clinician review. In clinician-guided mode, a clinician guides the scan in real time. A physician prescribes the device. The platform supports role-based workflows: an administrator can schedule appointments, a sonographer or midwife reviews scans and records findings, and a doctor gives the final sign-off. This frees doctors’ time for patients who need to be seen face to face. Results can be documented in the electronic medical record.

The FDA granted De Novo marketing authorization in an announcement dated November 3, 2025. The device is designed for use from week 14 through week 38 in single-fetus pregnancies. In a study of 100 women who scanned themselves in Israel, fetal heart activity was detected in 95.3 percent of cases. In the multicenter U.S. HOLA study, which supported the FDA authorization, 162 women at four institutions performed 1,370 scans. Fetal cardiac activity was assessed successfully in 99.2 percent of clinician-guided scans and 96.5 percent of app-guided scans. Pulsenmore’s announcement of its partnership with Ouma Health describes how home ultrasound is being added to a virtual maternity care platform that serves patients in maternity deserts and underserved communities.

What the clinical evidence shows

Published research also covers safety, patient experience, and hybrid care. A retrospective cohort found no significant association with preterm delivery or adverse neonatal outcomes among 4,460 users and 102,707 matched non-users. A randomized trial in women with previous pregnancy loss reported lower anxiety and higher maternal-fetal attachment, and a Sheba pilot of hybrid care for gestational diabetes reported 97.4 percent remote visit completion. Independent studies in the Netherlands, the United Kingdom, and Germany add feasibility data.

Limits and implementation points

Home ultrasound checks fetal wellbeing, and it does not replace diagnostic or scheduled in-clinic ultrasound examinations. Successful integration of home ultrasound into prenatal care requires a well-defined clinical pathway that combines remote imaging with in-person care when needed. Pulsenmore supports two complementary models: clinician-guided scans, performed with real-time guidance from a healthcare professional, and app-guided scans, which patients perform independently and submit for clinical review. Both approaches allow healthcare providers to extend prenatal care beyond the clinic while maintaining clinician-led interpretation and clear pathways for follow-up when needed. Implementation also requires compatible smartphones, reliable connectivity, and sufficient clinical capacity for timely scan review.

Practical Takeaways for health system leaders

First, identify the gaps in prenatal care created by distance, particularly the need for regular maternal and fetal assessments between clinic visits.

Second, build a connected care model that combines complementary technologies, including blood pressure monitoring, fetal heart rate monitoring, and clinician-reviewed home ultrasound, based on each patient’s clinical needs.

Third, establish a clear clinical workflow, with defined responsibilities for remote review, timely communication, and escalation when further evaluation is needed.

Finally, integrate remote care with essential in-person services and measure its impact on access, patient experience, clinical outcomes, and healthcare resource utilization.

Teams evaluating home ultrasound for patients far from a clinic can start at Pulsenmore’s home ultrasound page and the Pulsenmore resource center.

FAQs

Q: Does Pulsenmore ES replace in-person ultrasound for patients far from a clinic?

A: No. The system does not replace diagnostic or scheduled in-clinic ultrasound examinations. It adds fetal checks between visits, and the health system keeps in-person diagnostic ultrasound in the care pathway.

Q: Which patients can use Pulsenmore ES?

A: Pulsenmore ES is designed for use from week 14 of pregnancy and for single-fetus pregnancies. A physician prescription is required, and each device is personal and intended for one patient during one pregnancy. The treating clinician decides use based on the patient’s risk profile.

Q: How does a health system start offering Pulsenmore ES?

A: Healthcare providers and organizations interested in integrating Pulsenmore into their prenatal care programs can contact the company directly through its website. The Pulsenmore team works closely with each organization to understand its clinical needs, develop an appropriate care model, and support implementation. Once the program is established, eligible patients can access home ultrasound as part of their provider’s prenatal care services.

Q: Can Pulsenmore ES work for patients with limited connectivity?

A: Pulsenmore ES supports two scanning modes with different connectivity requirements. Clinician-guided scans require a live connection with a healthcare professional, while app-guided scans can be performed independently, without a live clinical session. However, internet connectivity is still required to transmit scans for clinician review. Healthcare providers should assess connectivity and smartphone compatibility when determining patient eligibility.

Q: What clinical evidence supports Pulsenmore ES?

A: Pulsenmore is supported by a growing body of clinical evidence, including a pivotal multicenter U.S. study involving 162 women and 1,370 scans, which supported its FDA De Novo authorization. A large real-world study in Israel compared pregnancy outcomes among 4,460 Pulsenmore users and more than 102,000 non-users, finding no significant association between home ultrasound use and adverse pregnancy outcomes. Additional published research has explored maternal anxiety, patient experience, and the integration of home ultrasound into hybrid prenatal care models, including studies in the Netherlands and Israel. Beyond clinical trials, Pulsenmore reports more than 270,000 home ultrasound scans performed in real-world settings.

Q: Is Pulsenmore ES available in the United States now?

A: Yes. Pulsenmore launched U.S. commercial operations in 2026, with initial agreements with the Center for Fetal Maternal Ultrasound in Los Angeles and TLC Perinatal Care in Maryland, followed by a partnership with Ouma Health to expand access to remote prenatal care. Healthcare providers interested in offering Pulsenmore home ultrasound can contact the company directly to learn more about the technology and integrate it into their prenatal care services. Once enrolled, eligible patients can purchase the device directly through Pulsenmore’s website with a prescription from their healthcare provider.

Q: How does reimbursement work for Pulsenmore home ultrasound in the U.S.?

A: Pulsenmore can be integrated into existing prenatal care models. Under a common commercial approach, healthcare providers offer the home ultrasound device to patients for a fee and may seek reimbursement from insurers for eligible ultrasound services performed and interpreted by clinicians. Reimbursement depends on the services provided, applicable billing codes, payer policies, and individual coverage arrangements. Pulsenmore works with healthcare organizations to explore clinical and commercial models that fit their practice.